In an expert view piece, Ronald Wisor (above, left) and Hein van den Bos — partners at the global law firm Hogan Lovells — discuss the challenges created by Europe's evolving transparency laws.
The 2010 Physician Payments Sunshine Act created a new standard of transparency for financial relationships between pharmaceutical companies and health care professionals in the USA. Now, countries across Europe are following suit by rolling out their own 'sunshine' rules. But these rules differ from country to country, which means navigating a challenging regulatory patchwork of nation-specific regulations, managing press around existing relationships, and dealing with new costs related to compliance.
In some countries, sunshine rules are laid down in the law itself and there are penalties for non-compliance. But in other countries, the rules are established by industry or physician codes of conduct and it is softer regulation, often without any penalties. And in some other countries, there aren't really sunshine rules at all.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze